top of page
  • Jonathan Poyer

Biotech Capital Market Environment: Sleuthing For Opportunities

Updated: Sep 16, 2022






There is value out there regardless of where inflation and the broader economy shakes out. Just look at Biotech and the week ending September 9th.


Positive clinical, regulatory and strategic news helped propel the S&P Biotechnology Select Index back up to the 200 day moving average.


Let's check out the IPO market thanks to our friends at LifeSci Partners:


Week ending September 9th, 2022:

  • Biotech: 1 transaction totaling just over $200M

  • Med Tech: No current week financings

2022:

  • 96 Biotech transactions totalling just over $11B vs. 2021YTD; 246 Biotech transactions totaling just under $33B

  • 40 Biotech transactions totaling just under $4B in Q2 2022 vs. Q2 2021: 64 Biotech transactions totaling just over $10B

  • 10 Med Tech transactions totaling just over $800M v. 2021 YTD: 62 Med Tech transactions totaling just under $10B

  • No Med Tech transactions in Q2 2022 v. Q2 2021: 13 Med Tech transactions totaling just over $1B

Private Transactions:

  • Biotech: 192 US Transactions / 43 European Transactions

  • Med Tech: 116 US Transactions / 15 European Transactions

There are companies out there expected to make money and return capital to shareholders in this rough environment


Another look at the 2021 IPO market and results through September 9th:



It appears more biotech management teams and investors are betting leading companies will continue to create value regardless of where inflation and the broader economy shake out. But it is no easy task to keep track or keep up.


31 views0 comments

Comments


bottom of page